Compare Natera Inc. Common Stock (NTRA) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Visa Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Visa Inc trades at $393.42 (market cap $743.55B). The key difference: Visa Inc is far larger — about 13× Natera Inc. Common Stock's market cap, and Visa Inc pays a 0.68% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Visa Inc for 115 Days on average.
| NTRA | V | |
|---|---|---|
Market Cap | $57.03B | $743.55B |
Volume | 1,131,157 | 7,478,804 |
Sector | Health | Financials |
52-Week High | $425.64 | $396.06 |
52-Week Low | $179.42 | $295.52 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $56.18B | $754.13B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Visa (V) trades at $391.43, up 0.55% today, showing strong momentum near its resistance level of $392. The stock maintains bullish technical signals with consistent earnings beats in recent quarters and robust profitability metrics including 50.78% net margin and 61.79% ROE. Recent developments include the launch of Intelligent Commerce Connect for AI-powered commerce and expanded stablecoin partnerships, positioning Visa at the forefront of payment innovation.
Visa presents a compelling investment case with 85% analyst buy ratings and a $423.29 consensus price target representing 8% upside. Strong fundamentals are supported by $40B revenue and $20.1B net income for 2025, though elevated valuation ratios (P/E 33.71) and emerging fintech competition pose risks. The stock's outlook remains positive given its dominant market position and AI-driven growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
